drugset / Trial / NCT06989359
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Timeline
- Start
- 2025-08-28
- Primary completion
- 2028-12-31
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QPI-1007 | Small interfering RNA (siRNA) | — | — |